Synopsis
Synopsis
0
CEP/COS
0
EU WC
0
KDMF
0
VMF
0
FDF
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. Isa 247
2. Isa(tx)247
3. Isa-247
4. Isatx247
5. Lupkynis
1. 515814-01-4
2. Lupkynis
3. Luveniq
4. Isatx-247
5. Voclosporin [usan]
6. Isatx247
7. Isa-247
8. Isa247
9. Lx211
10. Lx-211
11. R 1524
12. R-1524
13. Isa(tx)247
14. (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-ethyl-33-[(1r,2r,4e)-1-hydroxy-2-methylhepta-4,6-dienyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
15. 515814-00-3
16. 2pn063x6b1
17. Trans-isa 247
18. Voclera
19. Isa 247
20. (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-ethyl-33-((1r,2r,e)-1-hydroxy-2-methylhepta-4,6-dien-1-yl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone
21. Trans-isa-247
22. Voclosporin (usan/inn)
23. Voclosporin [usan:inn]
24. Isatx 247
25. Unii-2pn063x6b1
26. 3odi
27. Lx-214
28. Isatx-247; Luveniq
29. Voclosporin [mi]
30. Voclosporin [inn]
31. Voclosporin [mart.]
32. Voclosporin [who-dd]
33. E-isa247
34. Schembl12632344
35. Gtpl11388
36. Voclosporin [orange Book]
37. Chebi:135957
38. Dtxsid401030488
39. (e)-isa-247
40. Ex-a5922
41. At27977
42. Db11693
43. Hy-106638
44. Cs-0026210
45. R1524
46. D09033
47. Q7939256
48. Cyclosporin A, 6-((2s,3r,4r)-3-hydroxy-4-methyl-2-(methylamino)-6,8-nonadienoic Acid)-
49. (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-ethyl-33-[(1r,2r,4e)-1-hydroxy-2-methylhepta-4,6-dien-1-yl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-bis(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecone
50. 1,11-anhydro[l-alanyl-d-alanyl-n-methyl-l-leucyl-n-methyl-l-leucyl- N-methyl-l-valyl-[(2s,3r,4r,6e)-3-hydroxy-4-methyl- 2-(methylamino)nona-6,8-dienoyl][(2s)-2-aminobutanoyl]- N-methylglycyl-n-methyl-l-leucyl-l-valyl-n-methyl-l-leucine]
51. Cyclo (((e,z)-(2s,3r,4r)-3-hydroxy-4-methyl-2-(methylamino)nona-6,8-dienoyl)-l-2-aminobytyrl-n-methyl-glycyl-n-methyl-l-leucyl-l-valyl-n-methyl-l-leucyl-l-alanyl-d-alanyl-n-methyl-l-leucyl-n-methyl-l-leucyl-n-methyl-l-valyl)
52. Cyclo(l-alanyl-d-alanyl-n-methyl-l-leucyl-n-methyl-l-leucyl-n-methyl-l-valyl- ((2s,3r,4r,6e)-3-hydroxy-4-methyl-2-(methylamino)nona-6,8-dienoyl)-(2s)-2- Aminobutanoyl-n-methylglycyl-n-methyl-l-leucyl-l-valyl-n-methyl-l-leucyl)
53. Cyclosporin A, 6-((2s,3r,4r,6e)-3-hydroxy-4-methyl-2-(methylamino)-6,8- Nonadienoic Acid)-
Molecular Weight | 1214.6 g/mol |
---|---|
Molecular Formula | C63H111N11O12 |
XLogP3 | 7.9 |
Hydrogen Bond Donor Count | 5 |
Hydrogen Bond Acceptor Count | 12 |
Rotatable Bond Count | 16 |
Exact Mass | 1213.84136802 g/mol |
Monoisotopic Mass | 1213.84136802 g/mol |
Topological Polar Surface Area | 279 Ų |
Heavy Atom Count | 86 |
Formal Charge | 0 |
Complexity | 2380 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 12 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Voclosporin is used in combination with a background immunosuppressive regimen for the treatment of lupus nephritis. Safety has not been established in combination with cyclophosphamide.
Treatment of Systemic Lupus Erythematosus (SLE)
Treatment of non-infectious uveitis
Lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN).
Voclosporin inhibits calcineurin, leading to the inhibition of T cell activation by blocking the transcription of early inflammatory cytokines. This reduces inflammation in the kidney, treating lupus nephritis and preventing permanent renal damage.
L04AD03
L - Antineoplastic and immunomodulating agents
L04 - Immunosuppressants
L04A - Immunosuppressants
L04AD - Calcineurin inhibitors
L04AD03 - Voclosporin
Absorption
When administered on an empty stomach, the median Tmax of voclosporin is 1.5 hours, but can range from 1-4 hours. The AUC is estimated at 7693.6 ng/mL*h and the Cmax is estimated at 955.5 ng/mL.
Route of Elimination
Voclosporin is eliminated in the urine and feces, with about 88% detected in the feces and about 2% detected in the urine.
Volume of Distribution
The apparent volume of distribution of voclosporin is 2,154 L. Voclosporin distributes extensively into red blood cells; distribution between whole blood and plasma is dependent on concentration and temperature.
Clearance
The mean apparent steady-state clearance of voclosporin is 63.6 L/h. Hepatic and renal impairment significantly reduce the clearance of voclosporin.
Voclosporin is mainly metabolized by the CYP3A4 hepatic cytochrome enzyme. Pharmacologic activity is mainly attributed to the parent molecule. A major metabolite has been detected in human whole blood, representing 16.7% of total exposure; this metabolite is about 8-fold less potent than the parent drug, voclosporin.
The average terminal half-life of voclosporin is about 30 hours (24.9 to 36.5 hours).
Through the inhibition of calcineurin, voclosporin blocks IL-2 expression and T-cell mediated immune responses, stabilizing podocytes in the kidneys. Voclospoprin is a cyclosporine A analog. It is structurally similar to cyclosporine A (CsA) with the exception of an amino acid modification in one region. This modification changes the binding of voclosporin to calcineurin. Cyclosporine inhibitors reversibly inhibit T-lymphocytes. They also inhibit lymphokine production and release. Cyclosporine A exerts its inhibitory effects on T-lymphocytes by binding to cyclophilin. A cyclophilin-cyclosporine complex is formed, leading to the inhibition of calcium- and calmodulin-dependent serine-threonine phosphatase activity of calcineurin. Along with calcineurin inhibition, the inhibition of many transcription factors necessary for the induction of various cytokine genes such as IL-2, IFN-, IL-4 and GM-CSF occurs. This, in turn, reduces inflammation, treating renal glomerulonephritis associated with systemic lupus erythematosus.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Medichem is a vertically integrated pharmaceutical company specializing in the development & manufacturing of APIs & FDFs.
GDUFA
DMF Review : Reviewed
Rev. Date : 2024-09-11
Pay. Date : 2024-07-19
DMF Number : 40162
Submission : 2024-08-01
Status : Active
Type : II
NDC Package Code : 53296-0130
Start Marketing Date : 2024-08-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (75kg/75kg)
Marketing Category : BULK INGREDIENT
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
GDUFA
DMF Review : Reviewed
Rev. Date : 2024-09-19
Pay. Date : 2024-07-11
DMF Number : 39556
Submission : 2024-07-09
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33779
Submission : 2020-04-06
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2024-08-09
Pay. Date : 2024-06-10
DMF Number : 40089
Submission : 2024-07-24
Status : Active
Type : II
NDC Package Code : 47848-059
Start Marketing Date : 2022-04-04
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (100kg/100kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23335
Submission : 2009-12-02
Status : Inactive
Type : II
Medichem is a vertically integrated pharmaceutical company specializing in the development & manufacturing of APIs & FDFs.
GDUFA
DMF Review : Complete
Rev. Date : 2024-09-11
Pay. Date : 2024-07-19
DMF Number : 40162
Submission : 2024-08-01
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2024-09-19
Pay. Date : 2024-07-11
DMF Number : 39556
Submission : 2024-07-09
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23335
Submission : 2009-12-02
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33779
Submission : 2020-04-06
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2024-08-09
Pay. Date : 2024-06-10
DMF Number : 40089
Submission : 2024-07-24
Status : Active
Type : II
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Voclosporin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Voclosporin, including repackagers and relabelers. The FDA regulates Voclosporin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Voclosporin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Voclosporin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Voclosporin supplier is an individual or a company that provides Voclosporin active pharmaceutical ingredient (API) or Voclosporin finished formulations upon request. The Voclosporin suppliers may include Voclosporin API manufacturers, exporters, distributors and traders.
click here to find a list of Voclosporin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Voclosporin DMF (Drug Master File) is a document detailing the whole manufacturing process of Voclosporin active pharmaceutical ingredient (API) in detail. Different forms of Voclosporin DMFs exist exist since differing nations have different regulations, such as Voclosporin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Voclosporin DMF submitted to regulatory agencies in the US is known as a USDMF. Voclosporin USDMF includes data on Voclosporin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Voclosporin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Voclosporin suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Voclosporin Drug Master File in Japan (Voclosporin JDMF) empowers Voclosporin API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Voclosporin JDMF during the approval evaluation for pharmaceutical products. At the time of Voclosporin JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Voclosporin suppliers with JDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Voclosporin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Voclosporin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Voclosporin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Voclosporin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Voclosporin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Voclosporin suppliers with NDC on PharmaCompass.
Voclosporin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Voclosporin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Voclosporin GMP manufacturer or Voclosporin GMP API supplier for your needs.
A Voclosporin CoA (Certificate of Analysis) is a formal document that attests to Voclosporin's compliance with Voclosporin specifications and serves as a tool for batch-level quality control.
Voclosporin CoA mostly includes findings from lab analyses of a specific batch. For each Voclosporin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Voclosporin may be tested according to a variety of international standards, such as European Pharmacopoeia (Voclosporin EP), Voclosporin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Voclosporin USP).
LOOKING FOR A SUPPLIER?